Cognition & Affect After Stroke: a Prospective Evaluation of Risks

Status Completed

Clinical Trial Summary

Stroke is a leading cause of disability, affecting about 34,000 to 41,000 individuals in the Netherlands of middle and old age every year. Due to the aging of the population, this figure will increase considerably over the next decades (Struijs et al., 2005). Twenty-five percent of stroke patients die within one month, making stroke a major risk factor for premature death in developed countries. According to the World Health Organization, stroke is the third leading cause of the burden of disease in middle and high-income countries (World Health Organization, 2008). It has a significant negative impact on quality of life of both the patients as well as their caregivers and significant others. Surviving stroke patients often struggle with its manifold and lifelong lasting consequences, with 35 percent of patients being functionally dependent one year after stroke (Wolfe, 2000) and cognitive and emotional changes which are found up to two years post-stroke (Rasquin, Lodder, & Verhey, 2005). Depression, apathy, and cognitive impairment are very prevalent and significantly contribute to the burden of the disease, but their etiologies remain poorly understood. The aim of the CASPER study is to gain more insight into the etiologies of post-stroke depression (PSD), post-stroke apathy (PSA), vascular cognitive impairment (VCI), and post-stroke dementia. Therefore, the primary objectives are to identify biomarker-based predictors of PSD, PSA, and VCI. A secondary aim is to study effect modulation, especially the interaction between cerebrovascular disease, neurodegenerative changes and inflammation in post-stroke dementia. CASPER is a prospective clinical cohort study of 250 first-ever ischemic stroke patients with serial assessments at baseline (10 to 12 weeks after stroke), six and 12 months after baseline. Another wave (36 month after baseline) was later added.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02585349
Study type	Observational [Patient Registry]
Source	Maastricht University Medical Center
Contact
Status	Completed
Phase
Start date	April 1, 2013
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04567745` - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers	Phase 1
Recruiting	`NCT04109963` - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment	Phase 2
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Not yet recruiting	`NCT06416371` - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed	`NCT01761227` - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia	Phase 2
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT00165763` - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia	Phase 4
Completed	`NCT00621647` - Seroquel- Agitation Associated With Dementia	Phase 3
Recruiting	`NCT04095962` - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Active, not recruiting	`NCT03804229` - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia	Phase 3
Enrolling by invitation	`NCT03724136` - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	N/A
Completed	`NCT02453932` - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia	Phase 3
Completed	`NCT00947531` - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia	Phase 4
Not yet recruiting	`NCT03702543` - Managing Vascular Dementia Risk Factors With SymTrend	Phase 1
Enrolling by invitation	`NCT02147652` - Personalized Music Therapy and Agitation in Dementia	N/A
Recruiting	`NCT04114994` - Longitudinal Cognitive Assessment by BoCA
Recruiting	`NCT06034509` - Cognitive and Vascular Functioning Following TBI
Recruiting	`NCT05921266` - Urolithin A Supplementation in Middle-aged Adults With Obesity	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cognition and Affect After Stroke: a Prospective Evaluation of Risks — CASPER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms